These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3100126)

  • 1. Antimicrobial activity of LY164846, a new oral cephalosporin, and recommendations for disk diffusion tests.
    Sassine-Nawas G; Baker CN; Thornsberry C
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):41-8. PubMed ID: 3100126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
    Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of an orally administered cephalosporin, LY164846, against potentially pathogenic respiratory and dermal bacterial isolates.
    Lauderdale BL; Yu PK; Washington JA
    Antimicrob Agents Chemother; 1986 Apr; 29(4):560-4. PubMed ID: 3486628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY164846 in vitro antimicrobial activity testing, including disk diffusion susceptibility tests using 30-microgram disks.
    Jones RN; Baker C; Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1986 Mar; 29(3):530-4. PubMed ID: 3755018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antibacterial activity of a new oral cephalosporin, ceftibuten. Results of a multicenter study].
    Soussy CJ; Meyran M; Chanal M; Reverdy ME; Kitzis MD; Derlot E
    Pathol Biol (Paris); 1991 May; 39(5):396-402. PubMed ID: 1909017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
    Chin NX; Gu JW; Neu HC
    Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of MDL 19,592: an oral cephalosporin.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1988 Nov; 11(3):159-62. PubMed ID: 3246143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro antibacterial activity of RU 51746 (sodium salt of cefpodoxime). Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Kitzis MD; Chanal C; Mounier M; Derlot E; Vergnaud M
    Pathol Biol (Paris); 1990 May; 38(5):336-42. PubMed ID: 2195445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.
    Jones RN; Thornsberry C; Barry AL; Ayers L; Brown S; Daniel J; Fuchs PC; Gavan TL; Gerlach EH; Matsen JM
    J Clin Microbiol; 1984 Sep; 20(3):409-12. PubMed ID: 6490826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks.
    Jones RN; Barry AL; Thornsberry C
    Diagn Microbiol Infect Dis; 1983 Dec; 1(4):295-311. PubMed ID: 6321093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial effect of cefixime].
    Soussy CJ; Meyran M; Duval J
    Presse Med; 1989 Oct; 18(32):1546-50. PubMed ID: 2530528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMY 28100, a new oral cephalosporin.
    Leitner F; Pursiano TA; Buck RE; Tsai YH; Chisholm DR; Misiek M; Desiderio JV; Kessler RE
    Antimicrob Agents Chemother; 1987 Feb; 31(2):238-43. PubMed ID: 3105449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.
    Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE
    J Clin Microbiol; 1982 May; 15(5):769-76. PubMed ID: 6212595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
    Kayser FH
    Eur J Clin Microbiol; 1987 Jun; 6(3):309-12. PubMed ID: 3497804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefoperazone: spectrum of antibacterial activity and disc diffusion testing.
    Thornsberry C; Jones RN
    Drugs; 1981; 22 Suppl 1():3-12. PubMed ID: 6456889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity and beta-lactamase stability of MDL 19,592, an oral cephalosporin.
    Yu KW; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(5):441-3. PubMed ID: 2515027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
    Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH
    J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.